<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>HOFT_PBMC_TICE_BCG_RBCG_AG85A_AG85B_AGE_18_40YO_CORRELATED_WITH_WHOLE_BLOOD_BACTERICIDAL_ACTIVITY_NEGATIVE</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            HOFT_PBMC_TICE_BCG_RBCG_AG85A_AG85B_AGE_18_40YO_CORRELATED_WITH_WHOLE_BLOOD_BACTERICIDAL_ACTIVITY_NEGATIVE
        </div>
        <div class="card-body">
                <p>BACKGROUND: We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin. METHODS: This was a randomized, double-blind, dose-escalation trial in HIV-negative, healthy adult, BCG-naÃ¯ve volunteers, negative for prior exposure to Mtb, at one US clinical site. Volunteers were randomized 2:1 at each dose level to receive a single intradermal dose of AERAS-422 ( &gt; 10(5)- &lt; 10(6)CFU=low dose, â‰¥10(6)- &lt; 10(7)CFU=high dose) or non-recombinant Tice BCG (1-8Ã—10(5)CFU). Randomization used an independently prepared randomly generated sequence of treatment assignments. The primary and secondary outcomes were safety and immunogenicity, respectively, assessed in all participants through 182days post-vaccination. ClinicalTrials.gov registration number: NCT01340820. FINDINGS: Between Nov 2010 and Aug 2011, 24 volunteers were enrolled (AERAS-422 high dose, n=8; AERAS-422 low dose, n=8; Tice BCG, n=8); all were included in the safety and immunogenicity analyses. All 24 subjects had at least one adverse event, primarily expected local reactions. High dose AERAS-422 vaccination induced Ag85A- and Ag85B-specific lymphoproliferative responses and marked anti-mycobacterial activity in a whole blood bactericidal activity culture assay (WBA), but was associated with varicella zoster virus (VZV) reactivation in two vaccinees. These volunteers displayed high BCG-specific IFN-Î³ responses pre- and post-vaccination possibly predisposing them to autocrine/paracrine negative regulation of immune control of latent VZV. A systems biology transcriptomal approach identified positive correlations between post-vaccination T cell expression modules and WBA, and negative correlations between post-vaccination monocyte expression modules and WBA. The expression of one key macrophage marker (F4/80) was constitutively elevated in the two volunteers with zoster. INTERPRETATION: The unexpected development of VZV in two of eight healthy adult vaccine recipients resulted in discontinuation of AERAS-422 vaccine development. Immunological and transcriptomal data identified correlations with the development of TB immunity and VZV that require further investigation. FUNDING: Aeras, FDA, Bill and Melinda Gates Foundation.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M41034">M41034</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:9606">NCBITaxon:9606</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:3595">ncbigene:3595</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:56907">ncbigene:56907</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9254">ncbigene:9254</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2999">ncbigene:2999</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:494470">ncbigene:494470</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:11098">ncbigene:11098</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:80310">ncbigene:80310</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:221002">ncbigene:221002</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8292">ncbigene:8292</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3560">ncbigene:3560</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3820">ncbigene:3820</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:10578">ncbigene:10578</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6352">ncbigene:6352</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5551">ncbigene:5551</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:7049">ncbigene:7049</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:90102">ncbigene:90102</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3486">ncbigene:3486</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:343413">ncbigene:343413</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:51348">ncbigene:51348</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:116987">ncbigene:116987</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:919">ncbigene:919</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8671">ncbigene:8671</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:29799">ncbigene:29799</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:23345">ncbigene:23345</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:83888">ncbigene:83888</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:84525">ncbigene:84525</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9437">ncbigene:9437</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:117157">ncbigene:117157</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:493">ncbigene:493</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8530">ncbigene:8530</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:79899">ncbigene:79899</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:55784">ncbigene:55784</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3811">ncbigene:3811</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:84443">ncbigene:84443</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:284367">ncbigene:284367</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:10316">ncbigene:10316</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3002">ncbigene:3002</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:4818">ncbigene:4818</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:115">ncbigene:115</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:79071">ncbigene:79071</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M41034&#39;, name=&#39;HOFT_PBMC_TICE_BCG_RBCG_AG85A_AG85B_AGE_18_40YO_CORRELATED_WITH_WHOLE_BLOOD_BACTERICIDAL_ACTIVITY_NEGATIVE&#39;), definition=&#39;BACKGROUND: We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin. METHODS: This was a randomized, double-blind, dose-escalation trial in HIV-negative, healthy adult, BCG-naÃ¯ve volunteers, negative for prior exposure to Mtb, at one US clinical site. Volunteers were randomized 2:1 at each dose level to receive a single intradermal dose of AERAS-422 ( &gt; 10(5)- &lt; 10(6)CFU=low dose, â‰¥10(6)- &lt; 10(7)CFU=high dose) or non-recombinant Tice BCG (1-8Ã—10(5)CFU). Randomization used an independently prepared randomly generated sequence of treatment assignments. The primary and secondary outcomes were safety and immunogenicity, respectively, assessed in all participants through 182days post-vaccination. ClinicalTrials.gov registration number: NCT01340820. FINDINGS: Between Nov 2010 and Aug 2011, 24 volunteers were enrolled (AERAS-422 high dose, n=8; AERAS-422 low dose, n=8; Tice BCG, n=8); all were included in the safety and immunogenicity analyses. All 24 subjects had at least one adverse event, primarily expected local reactions. High dose AERAS-422 vaccination induced Ag85A- and Ag85B-specific lymphoproliferative responses and marked anti-mycobacterial activity in a whole blood bactericidal activity culture assay (WBA), but was associated with varicella zoster virus (VZV) reactivation in two vaccinees. These volunteers displayed high BCG-specific IFN-Î³ responses pre- and post-vaccination possibly predisposing them to autocrine/paracrine negative regulation of immune control of latent VZV. A systems biology transcriptomal approach identified positive correlations between post-vaccination T cell expression modules and WBA, and negative correlations between post-vaccination monocyte expression modules and WBA. The expression of one key macrophage marker (F4/80) was constitutively elevated in the two volunteers with zoster. INTERPRETATION: The unexpected development of VZV in two of eight healthy adult vaccine recipients resulted in discontinuation of AERAS-422 vaccine development. Immunological and transcriptomal data identified correlations with the development of TB immunity and VZV that require further investigation. FUNDING: Aeras, FDA, Bill and Melinda Gates Foundation.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;27322481&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;9606&#39;, name=&#39;Homo sapiens&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3595&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;56907&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9254&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2999&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;494470&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;11098&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;80310&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;221002&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8292&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3560&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3820&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;10578&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6352&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5551&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7049&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;90102&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3486&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;343413&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;51348&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;116987&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;919&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8671&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;29799&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;23345&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;83888&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;84525&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9437&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;117157&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;493&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8530&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;79899&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;55784&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3811&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;84443&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;284367&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;10316&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3002&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;4818&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;115&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;79071&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C7&#39;], &#39;sub_category_code&#39;: [&#39;VAX&#39;], &#39;contributor&#39;: [&#39;HIPC SIGNATURES&#39;], &#39;exact_source&#39;: [&#39;Fig 7A&#39;], &#39;external_details_url&#39;: [&#39;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909487/figure/f0035/&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>